Clinical characteristics of patients with secondary CNS lymphoma
| Characteristic . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . |
|---|---|---|---|---|
| Age, y | 82 | 56 | 40 | 41 |
| Sex | M | F | F | F |
| No. of lines of prior therapy | 4 | 4 | 4 | 5 |
| Prior therapies | 1. R-miniCHOP 2. Lenalidomide 3. Focal RT 4. Lisocabtagene maraleucel | 1. R-CHOP 2. High-dose MTX 3. R-GDP 4. Axicabtagene ciloleucel | 1. R-HyperCVAD 2. WBRT 3. AVM0703 4. Lisocabtagene maraleucel | 1. R-CHOP 2. HyperCVAD 3. WBRT 4. R-GemOx 5. Lisocabtagene maraleucel |
| Sites of disease | CNS parenchyma | Bone, leptomeninges, and CSF | CNS parenchyma | CNS parenchyma and cranial nerves |
| Concomitant therapies | None | Obinutuzumab pretreatment and intrathecal MTX | Obinutuzumab pretreatment, focal RT, corticosteroids, and acalabrutinib | Focal RT, corticosteroids, and acalabrutinib |
| Timing of CSF collection | 9 d after C4D1 | 16 h after C2D1 | 18 d after C3D1 | 18 d after C2D1 |
| CRS or ICANS | Gr 2 CRS after C1D1 | Gr 1 CRS after C1D8 | No | No |
| No. of glofitamab cycles | ≥8 | ≥6 | ≥7 | 2 |
| Glofitamab response | PR | CR | PR | PD |
| CSF cellular composition | NA | Preglofitamab: 29 leukocytes/μL 12 lymphocytes/μL 42% lymphoma cells 3 d postglofitamab: 366 leukocytes/μL 48 lymphocytes/μL 3% lymphoma cells | NA | NA |
| Characteristic . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . |
|---|---|---|---|---|
| Age, y | 82 | 56 | 40 | 41 |
| Sex | M | F | F | F |
| No. of lines of prior therapy | 4 | 4 | 4 | 5 |
| Prior therapies | 1. R-miniCHOP 2. Lenalidomide 3. Focal RT 4. Lisocabtagene maraleucel | 1. R-CHOP 2. High-dose MTX 3. R-GDP 4. Axicabtagene ciloleucel | 1. R-HyperCVAD 2. WBRT 3. AVM0703 4. Lisocabtagene maraleucel | 1. R-CHOP 2. HyperCVAD 3. WBRT 4. R-GemOx 5. Lisocabtagene maraleucel |
| Sites of disease | CNS parenchyma | Bone, leptomeninges, and CSF | CNS parenchyma | CNS parenchyma and cranial nerves |
| Concomitant therapies | None | Obinutuzumab pretreatment and intrathecal MTX | Obinutuzumab pretreatment, focal RT, corticosteroids, and acalabrutinib | Focal RT, corticosteroids, and acalabrutinib |
| Timing of CSF collection | 9 d after C4D1 | 16 h after C2D1 | 18 d after C3D1 | 18 d after C2D1 |
| CRS or ICANS | Gr 2 CRS after C1D1 | Gr 1 CRS after C1D8 | No | No |
| No. of glofitamab cycles | ≥8 | ≥6 | ≥7 | 2 |
| Glofitamab response | PR | CR | PR | PD |
| CSF cellular composition | NA | Preglofitamab: 29 leukocytes/μL 12 lymphocytes/μL 42% lymphoma cells 3 d postglofitamab: 366 leukocytes/μL 48 lymphocytes/μL 3% lymphoma cells | NA | NA |
CSF, cerebrospinal fluid; CR, complete response; CRS, cytokine release syndrome; CxDx, cycle and day of glofitamab treatment; F, female; Gr, grade; ICANS, immune effector cell–associated neurotoxicity syndrome; M, male; MTX, methotrexate; NA, not applicable; PD, progressive disease; PR, partial response; R-CHOP, rituximab, cyclophosphamide, hydroxydaunorubicin, Oncovin (vincristine), and prednisone; R-GDP, rituximab, gemcitabine, dexamethasone, and cisplatin; R-GemOx, rituximab, gemcitabine, and oxaliplatin; R-HyperCVAD, rituximab, cyclophosphamide, vincristine, Adriamycin (doxorubicin), and dexamethasone; R-miniCHOP, rituximab, reduced dose cyclophosphamide, hydroxydaunorubicin, Oncovin (vincristine), and prednisone; RT, radiotherapy; WBRT, whole brain radiotherapy.